Published in conjunction with the 2016 ASCO Annual Meeting
Myeloid growth factor support (GFs) reduces the incidence/duration of neutropenia and facilitates dose intensity. GFs is recommended by ASCO guidelines when the risk of chemotherapy induced febrile neutropenia (FN) exceeds 20% and may be considered for 10-20% FN risks. Most adjuvant breast cancer regimens fall into the 10-20% category.
Authors: Hyun gi Noh, Dhakshila Paramanathan, Kiran Suryadevara, Kelly Choi, Augie Smith, William Kea, Eric V Schultz, Andrew Pecora, Stuart L. Goldberg; COTA, New York, NY